New CAR-T therapy targets Hard-to-Treat myeloma
NCT ID NCT07322159
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tests a new treatment called IASO206 for people with multiple myeloma that has come back or stopped responding to standard therapies. IASO206 is a type of CAR-T therapy that uses a patient's own immune cells to attack cancer cells. The trial will enroll 12 adults aged 18-75 and focus on safety and how well the treatment works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- IASO206 (a CAR-T cell therapy that targets BCMA on myeloma cells)
- What this could lead to
- If it works, this could point toward a new treatment option for multiple myeloma that has stopped responding to other therapies.
- What could go wrong
- This is a very early, small trial (12 people) focused on safety. It may not show strong effectiveness, and side effects like cytokine release syndrome are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New hope for tough myeloma: early trial of BP2202 begins
- Can a Pre-Dose prevent a dangerous reaction in multiple myeloma treatment?
- New drug combo aims to tackle Hard-to-Treat myeloma
- New hope for myeloma patients: epunamin combo under study
- New combo therapy aims to tackle Hard-to-Treat myeloma
- New drug duo aims to tackle Hard-to-Treat myeloma